Aptose Biosciences (APTO) 6-K 6 Nov 18 2018 Q3 Condensed Consolidated Interim Statements of Financial Position Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2018
Document Information [Line Items]
Entity Registrant Name	Aptose Biosciences Inc.
Entity Central Index Key	882,361
Trading Symbol	apto
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Document Type	6-K
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Interim

Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents (note 4(a))	$ 15,056	$ 10,631
Investments (note 4(b))	550	798
Prepaid expenses and other assets	459	396
Total current assets	16,065	11,825
Non-current assets
Property and equipment	230	142
Total non-current assets	230	142
Total assets	16,295	11,967
Current liabilities
Accounts payable and accrued liabilities	2,370	1,765
Total current liabilities	2,370	1,765
Shareholders’ equity:
Common shares (note 6)	254,715	231,923
Stock options (note 7)	9,950	6,456
Contributed surplus	22,950	22,909
Accumulated other comprehensive loss	(4,298)	(4,298)
Deficit	(269,392)	(246,788)
Total shareholders’ equity	13,925	10,202
Total liabilities and shareholders’ equity	$ 16,295	$ 11,967

Condensed Consolidated Interi_2

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Revenue
Expenses:
Research and development (note 9)	3,591	1,390	14,549	4,213
General and administrative (note 9)	2,020	1,319	8,233	4,302
Operating Expenses	5,611	2,709	22,782	8,515
Finance expense (note 9)			20
Finance income (note 9)	(89)	(69)	(198)	(142)
Net finance income	(89)	(69)	(178)	(142)
Net loss and comprehensive loss for the period	$ (5,522)	$ (2,640)	$ (22,604)	$ (8,373)
Basic and diluted loss per common share (in dollars per share)	$ (0.16)	$ (0.11)	$ (0.71)	$ (0.40)
Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (000s) note 6(b) (in shares)	34,587	24,061	32,039	20,954

Condensed Consolidated Interi_3

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Issued capital [member]	Reserve of share-based payments [member]	Share premium [member]	Accumulated other comprehensive income [member]	Retained earnings [member]	Total
Balance (in shares) at Dec. 31, 2016	15,722
Balance at Dec. 31, 2016	$ 218,034	$ 7,306	$ 21,413	$ (4,298)	$ (235,127)	$ 7,328
Statement Line Items [Line Items]
Common shares issued (in shares)	8,858
Common shares issued	$ 10,203					10,203
Stock-based compensation (note 7)		666				666
Expiry of vested stock options		(1,487)	1,487
Net loss for the period					(8,373)	(8,373)
Common shares issued on redemption of restricted share units (note 7) (in shares)	150
Common shares issued on redemption of restricted share units (note 7)	$ 171	(171)
Balance (in shares) at Sep. 30, 2017	24,730
Balance at Sep. 30, 2017	$ 228,408	6,314	22,900	(4,298)	(243,500)	9,824
Balance (in shares) at Dec. 31, 2017	27,502
Balance at Dec. 31, 2017	$ 231,923	6,456	22,909	(4,298)	(246,788)	10,202
Statement Line Items [Line Items]
Common shares issued (in shares)	2,017
Common shares issued	$ 6,818					6,818
Common shares issued pursuant to 2017 Share Purchase Agreement (note 6(a)(ii)) (in shares)	5,232
Common shares issued pursuant to 2017 Share Purchase Agreement (note 6(a)(ii))	$ 14,995					14,995
Common shares issued pursuant to 2018 Share Purchase Agreement (note 6(a)(iii)) (in shares)	170
Common shares issued pursuant to 2018 Share Purchase Agreement (note 6(a)(iii))	$ 600					600
Common shares issued upon exercise of stock options (note 7) (in shares)	96
Common shares issued upon exercise of stock options (note 7)	$ 379	(160)				219
Stock-based compensation (note 7)		3,695				3,695
Expiry of vested stock options		(41)	41
Net loss for the period					(22,604)	(22,604)
Balance (in shares) at Sep. 30, 2018	35,017
Balance at Sep. 30, 2018	$ 254,715	$ 9,950	$ 22,950	$ (4,298)	$ (269,392)	$ 13,925

Condensed Consolidated Interi_4

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss for the period	$ (5,522)	$ (2,640)	$ (22,604)	$ (8,373)
Items not involving cash:
Stock-based compensation	952	156	3,695	666
Shares issued to Aspire Capital as commitment fees (note 6(a)(iii))			600
Depreciation and amortization	29	20	64	66
Interest income	(80)	(21)	(198)	(40)
Unrealized foreign exchange (loss) gain	(28)	(48)	(2)	(98)
Change in non-cash operating working capital (note 8)	101	442	542	395
Cash used in operating activities	(4,548)	(2,091)	(17,903)	(7,384)
Cash flows from financing activities:
Issuance of common shares under the 2018 ATM, net of issuance costs (note 6(a)(i))	1,572		6,818
Issuance of common shares under Share Purchase Agreement (note 6(a)(ii))			14,995
Issuance of common shares under the ATM, net of issuance costs (note 6(a)(iv))		1,999		10,203
Issuance of common shares upon exercise of stock options (note 7)	36		219
Cash provided by financing activities	1,608	1,999	22,032	10,203
Cash flows from (used in) investing activities:
Maturity (acquisition) of investments		(9)	250	(2,994)
Purchase of property and equipment	(28)		(152)
Interest received	80	21	198	40
Cash provided by (used in) investing activities	52	12	296	(2,954)
Effect of exchange rate fluctuations on cash and cash equivalents held		48		98
Increase (decrease) in cash and cash equivalents	(2,888)	(32)	4,425	(37)
Cash and cash equivalents, beginning of period	17,944	7,935	10,631	7,940
Cash and cash equivalents, end of period	$ 15,056	$ 7,903	$ 15,056	$ 7,903

Note 1 - Reporting Entity

Note 1 - Reporting Entity	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of notes and other explanatory information [text block]	1. Aptose Biosciences Inc. ("Aptose" or the "Company") is a clinical-stage biotechnology company committed to developing highly differentiated therapeutics that target the underlying mechanisms and unmet medical needs in oncology. Aptose is a publicly listed company incorporated under the laws of Canada. The Company's shares are listed on the Nasdaq Capital Markets and the Toronto Stock Exchange. The head office, principal address and records of the Company are located at 251 1105, M2J 4R3.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of basis of preparation of financial statements [text block]	2. (a) Statement of Compliance These unaudited condensed consolidated interim financial statements of the Company as at September 30, 2018, 34, Interim Financial Reporting not not three nine September 30, 2018, not may December 31, 2018. December 31, 2017. The unaudited condensed consolidated interim financial statements of the Company were reviewed by the Audit Committee and approved and authorized for issue by the Board of Directors on November 6, 2018. (b) Functional and presentation currency The functional and presentation currency of the Company is the US dollar. (c) Significant accounting judgments, estimates and assumptions The preparation of these unaudited condensed consolidated interim financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the unaudited condensed consolidated interim financial statements and reported amounts of revenues and expenses during the reporting period. Actual outcomes could differ from these estimates. Management’s assessment of the Company’s ability to continue as a going concern involves making a judgment, at a particular point in time, about inherently uncertain future outcomes and events or conditions. Please see note 5 The unaudited condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the unaudited condensed consolidated interim financial statements, and may

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of significant accounting policies [text block]	3. The accompanying unaudited condensed consolidated interim financial statements follow the same accounting policies and methods of application as the audited consolidated financial statements of the Company for the year ended December 31, 2017, a) Policies adopted in the period IFRS 9, Financial Instruments 9" IFRS 9 2014 9 2014 9 2014 not not b) Recent accounting pronouncements not IFRS 16, Leases 16” On January 13, 2016, 16 Leases January 1, 2019. 16 17 12 not

Note 4 - Capital Disclosures

Note 4 - Capital Disclosures	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of capital [text block]	4. Our primary objective when managing capital is to ensure that we have sufficient cash resources to fund our development activities and to maintain our ongoing operations. To secure the additional capital necessary to pursue these plans, we may We include cash and cash equivalents and short-term investments in the definition of capital. We are not no three nine September 30, 2018. In March 2018, “2018 $100,000,000 may one may 2018 may second “2018 Under the terms of the ATM facility with Cantor Fitzgerald, we may, $30 2018 $20.0 30 (a) Cash and cash equivalents: Cash and cash equivalents consists of cash of $832 December 31, 2017 - $3.225 three $14.224 December 31, 2017 - $7.406 (b) Investments: As at September 30, 2018 December 31, 2017, October 10, 2018, 1.45%.

Note 5 - Financial Instruments

Note 5 - Financial Instruments	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of financial instruments [text block]	5. (a) Financial instruments The Company financial instruments are as follows: As at As at Financial assets Cash and cash equivalents (consisting of high interest savings accounts, treasury bill and short-term bankers’ acceptance), measured at amortized cost $ 15,056 $ 10,631 Investments, consisting of fixed income securities, measured at amortized cost 550 798 Financial liabilities Accounts payable and accrued liabilities, measured at amortized cost $ 2,370 $ 1,765 At September 30, 2018, no (b) Financial risk management The Company has exposure to credit risk, liquidity risk, foreign currency risk and market risk. The Company's Board of Directors has the overall responsibility for the oversight of these risks and reviews the Company's policies on an ongoing basis to ensure that these risks are appropriately managed. (i) Credit risk Credit risk is the risk of financial loss to the Company if a customer, partner or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's cash and cash equivalents. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk for its cash and cash equivalents and short-term investments by maintaining minimum standards of R1 (ii) Liquidity risk Liquidity risk is the risk that the Company will not not In managing its liquidity risk, the Company has considered its available cash and cash equivalents and short-term investments as at September 30, 2018. 2018 twelve September 30, 2019. After considering the above factors, management has concluded that there are no may may (iii) Foreign currency risk Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. We are exposed to currency risk from employee costs as well as the purchase of goods and services for activities in Canada and the cash balances held in foreign currencies. Fluctuations in the Canadian dollar exchange rate could potentially have a significant impact on the Company’s results. Assuming all other variables remain constant, a 10% $78 September 30, 2018, CA$ Balances at CA$ Balances at Cash and cash equivalents $ 154 $ 83 Investments 710 1,000 Accounts payable and accrued liabilities (247 ) (384 ) Balance, end of period $ 617 $ 699 The Company does not (iv) Market risk Market risk is the risk that changes in market prices, such as interest rates, foreign exchange rates and equity prices will affect the Company's income or the value of its financial instruments. The Company is subject to interest rate risk on its cash and cash equivalents and investments. The Company does not not

Note 6 - Share Capital

Note 6 - Share Capital	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of share capital, reserves and other equity interest [text block]	6. The Company is authorized to issue an unlimited number of common shares. (a) Equity issuances: i) 2018 On March 28, 2018, may, $30 During the nine September 30, 2018, 2,017,046 $3.49 $7.0 $6.8 3% ii) 2017 On October 27, 2017, $15,500,000 30 October 31, 2017, 357,143 $500 $324 321,429 September 30, 2018, $15.5 . During the nine September 30, 2018, 5,231,953 $2.87 $15 iii) 2018 On May 30, 2018, 2018 $20 30 June 8, 2018, 170,261 2018 $600 September 30, 2018, not 2018 iv) 2015 On April 2, 2015, $20 December 29, 2017 $20 During the nine September 30, 2017, 8,858,252 $1.20 $10.62 $10.31 3% (b) Loss per share Loss per common share is calculated using the weighted average number of common shares outstanding for the three nine September 30, 2018 2017 Three months ended Nine months ended 2018 2017 2018 2017 Issued common shares, beginning of period 34,411 23,345 27,502 15,722 Effect of ATM issuances 174 716 693 5,180 Effect of shares issued pursuant to share purchase agreements - - 3,814 - Effect of exercise of stock options 2 - 30 - Effect of RSUs redemptions - - - 52 34,587 24,061 32,039 20,954 The effect of any potential exercise of our stock options outstanding during the period has been excluded from the calculation of diluted loss per common share as it would be anti-dilutive.

Note 7 - Other Equity

Note 7 - Other Equity	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of share-based payment arrangements [text block]	7. (a) Stock options transactions for the period: Nine months ended Nine months ended Number of Weighted Number of Weighted Outstanding, Beginning of period 2,344 $ 3.46 2,005 $ 4.31 Granted 2,284 2.99 780 1.14 Exercised (96 ) 2.28 - - Forfeited (51 ) 2.34 (165 ) 3.34 Expired (10 ) 4.97 (320 ) 4.60 Outstanding, end of period 4,471 $ 3.21 2,300 3.52 (b) Stock options outstanding at September 30, 2018: Options outstanding Options exercisable Range of exercise prices Options Weighted average remaining contractual life (years) Weighted average exercise price Options Weighted average exercise price $1.03-$2.76 912 8.5 1.45 536 $ 1.64 $2.77-$2.95 687 9.3 2.80 670 2.80 $2.96-$3.11 1,466 8.9 3.06 180 2.96 $3.12-$4.53 704 6.8 4.07 509 4.36 $4.54-$19.51 702 5.9 5.36 664 5.36 4,471 8.10 3.21 2,559 $ 3.54 (c) Fair value assumptions The following table presents the weighted average assumptions that were used in the Black-Scholes option pricing model to determine the fair value of stock options granted during the period, and the resultant weighted average fair values: Nine months ended Nine months ended Weighted average risk-free interest rate 2.43 % 1.27 % Expected dividend yield — — Weighted average expected volatility 93.4 % 98.4 % Weighted average expected life of options (in years) 5 5 Weighted average grant date fair value $ 2.23 $ 0.84 The Company uses historical data to estimate the expected dividend yield and expected volatility of its common shares in determining the fair value of stock options. The expected life of the options represents the estimated length of time the options are expected to remain outstanding. Stock options granted by the Company during the nine September 30, 2018 50% one 16.67% three 166,000 50% one 25% two 850,000 three nine September 30, 2018, $515 2017 $156 $3.258 2017 $495 Refer to note 9 The Company has available up to 6,127,965 options, rights and other entitlements under the stock-based compensation plans of the September 30, 2018. (d) Restricted share units The Company has a stock incentive plan (SIP) pursuant to which the Board may one nine September 30, 2018, Nine months ended, Nine months ended, Number Weighted average grant date fair value Number Weighted average Outstanding, beginning of period - $- - $- Granted 150 3.35 150 1.14 Redeemed - - (150 ) 1.14 Outstanding, end of period 150 $ 3.35 - $ - On March 28, 2017 150,000 three July 13, 2018, 150,000 three three nine September 30, 2018, $437 2017 nil $437 2017 $171 The grant date fair value of the July 13, 2018 Nasdaq Stock Exchange March 28, 2017 Toronto Stock Exchange

Note 8 - Additional Cash Flow D

Note 8 - Additional Cash Flow Disclosures	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of cash flow statement [text block]	8. Net change in non-cash operating working capital is summarized as follows: Three months ended Nine months ended 2018 2017 2018 2017 Prepaid expenses and other assets $ 134 $ 123 $ (63 ) $ 385 Accrued payables and accrued liabilities (33 ) 319 605 10 Net (used) provided $ 101 $ 442 $ 542 $ 395

Note 9 - Other Expenses

Note 9 - Other Expenses	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Components of other expenses [text block]	9. Components of research and development expenses: Three months ended Nine months ended 2018 2017 2018 2017 Program costs, excluding salaries $ 2,773 $ 1,017 $ 7,249 $ 2,956 Salaries 502 321 1,448 1,064 License fee, CrystalGenomics (a),(b) - - 5,000 - Stock-based compensation 307 43 826 168 Depreciation and amortization 9 9 26 25 $ 3,591 $ 1,390 $ 14,549 $ 4,213 a) On May 7, 2018, $2.0 806 10. b) On June 13, 2018, $3.0 806 10. Components of general and administrative expenses: Three months ended Nine months ended 2018 2017 2018 2017 General and administrative excluding salaries $ 853 $ 712 $ 3,149 $ 1,980 Salaries 503 483 1,577 1,784 Stock-based payment financing fees (note 6(a)(iii) - - 600 - Stock-based compensation 644 112 2,869 498 Depreciation and amortization 20 12 38 40 $ 2,020 $ 1,319 $ 8,233 $ 4,302 Components of finance expense: Three months ended Nine months ended 2018 2017 2018 2017 Foreign exchange loss $ - $ - $ 20 $ - Components of finance income: Three months ended Nine months ended 2018 2017 2018 2017 Interest income $ 80 $ 21 $ 198 $ 40 Foreign exchange gain 9 48 - 102 $ 89 $ 69 $ 198 $ 142

Note 10 - Commitments, Continge

Note 10 - Commitments, Contingencies and Guarantees	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of other provisions, contingent liabilities and contingent assets [text block]	10. Less than 1 year 1 – 3 years 3 – 5 years Greater than 5 years Total Operating leases $ 440 $ 915 $ 706 $ - $ 2,061 The Company has entered into various contracts with service providers with respect to the clinical development of APTO- 253 CG’806. $3.5 The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may Under the license agreement with CrystalGenomics, the Company has obligations for development milestones of $16 2 $44 may not On June 13, 2018, 806 $6 2 $20 may not

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of related party [text block]	11. The Company uses Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company. Dr. Stephen Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and oversees the laboratory work. The work is completed under the terms of research services agreements executed in March 2015 March 2018, twelve $300,000. During the nine September 30, 2018, $215 2017 $179

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of events after reporting period [text block]	12. Subsequent to the quarter end the Company issued 1,901,279 $3.69 707,547 2018 $1.5 three December 31, 2018.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Discloure of Significant Accounting Policies
Description of accounting policy for new accounting pronouncements [text block]	a) Policies adopted in the period IFRS 9, Financial Instruments 9" IFRS 9 2014 9 2014 9 2014 not not b) Recent accounting pronouncements not IFRS 16, Leases 16” On January 13, 2016, 16 Leases January 1, 2019. 16 17 12 not

Note 5 - Financial Instruments

Note 5 - Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of detailed information about financial instruments [text block]	As at As at Financial assets Cash and cash equivalents (consisting of high interest savings accounts, treasury bill and short-term bankers’ acceptance), measured at amortized cost $ 15,056 $ 10,631 Investments, consisting of fixed income securities, measured at amortized cost 550 798 Financial liabilities Accounts payable and accrued liabilities, measured at amortized cost $ 2,370 $ 1,765
Disclosure of currency risk [text block]	CA$ Balances at CA$ Balances at Cash and cash equivalents $ 154 $ 83 Investments 710 1,000 Accounts payable and accrued liabilities (247 ) (384 ) Balance, end of period $ 617 $ 699

Note 6 - Share Capital (Tables)

Note 6 - Share Capital (Tables)	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of earnings per share [text block]	Three months ended Nine months ended 2018 2017 2018 2017 Issued common shares, beginning of period 34,411 23,345 27,502 15,722 Effect of ATM issuances 174 716 693 5,180 Effect of shares issued pursuant to share purchase agreements - - 3,814 - Effect of exercise of stock options 2 - 30 - Effect of RSUs redemptions - - - 52 34,587 24,061 32,039 20,954

Note 7 - Other Equity (Tables)

Note 7 - Other Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of number and weighted average exercise prices of share options [text block]	Nine months ended Nine months ended Number of Weighted Number of Weighted Outstanding, Beginning of period 2,344 $ 3.46 2,005 $ 4.31 Granted 2,284 2.99 780 1.14 Exercised (96 ) 2.28 - - Forfeited (51 ) 2.34 (165 ) 3.34 Expired (10 ) 4.97 (320 ) 4.60 Outstanding, end of period 4,471 $ 3.21 2,300 3.52
Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]	Options outstanding Options exercisable Range of exercise prices Options Weighted average remaining contractual life (years) Weighted average exercise price Options Weighted average exercise price $1.03-$2.76 912 8.5 1.45 536 $ 1.64 $2.77-$2.95 687 9.3 2.80 670 2.80 $2.96-$3.11 1,466 8.9 3.06 180 2.96 $3.12-$4.53 704 6.8 4.07 509 4.36 $4.54-$19.51 702 5.9 5.36 664 5.36 4,471 8.10 3.21 2,559 $ 3.54
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]	Nine months ended Nine months ended Weighted average risk-free interest rate 2.43 % 1.27 % Expected dividend yield — — Weighted average expected volatility 93.4 % 98.4 % Weighted average expected life of options (in years) 5 5 Weighted average grant date fair value $ 2.23 $ 0.84
Disclosure of number and weighted average exercise prices of other equity instruments [text block]	Nine months ended, Nine months ended, Number Weighted average grant date fair value Number Weighted average Outstanding, beginning of period - $- - $- Granted 150 3.35 150 1.14 Redeemed - - (150 ) 1.14 Outstanding, end of period 150 $ 3.35 - $ -

Note 8 - Additional Cash Flow_2

Note 8 - Additional Cash Flow Disclosures (Tables)	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Net change in non-cash operating working capital [text block]	Three months ended Nine months ended 2018 2017 2018 2017 Prepaid expenses and other assets $ 134 $ 123 $ (63 ) $ 385 Accrued payables and accrued liabilities (33 ) 319 605 10 Net (used) provided $ 101 $ 442 $ 542 $ 395

Note 9 - Other Expenses (Tables

Note 9 - Other Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of components of research and development expense [text block]	Three months ended Nine months ended 2018 2017 2018 2017 Program costs, excluding salaries $ 2,773 $ 1,017 $ 7,249 $ 2,956 Salaries 502 321 1,448 1,064 License fee, CrystalGenomics (a),(b) - - 5,000 - Stock-based compensation 307 43 826 168 Depreciation and amortization 9 9 26 25 $ 3,591 $ 1,390 $ 14,549 $ 4,213
Disclosure of components of general and administrative expense [text block]	Three months ended Nine months ended 2018 2017 2018 2017 General and administrative excluding salaries $ 853 $ 712 $ 3,149 $ 1,980 Salaries 503 483 1,577 1,784 Stock-based payment financing fees (note 6(a)(iii) - - 600 - Stock-based compensation 644 112 2,869 498 Depreciation and amortization 20 12 38 40 $ 2,020 $ 1,319 $ 8,233 $ 4,302
Disclosure of finance income (cost) [text block]	Three months ended Nine months ended 2018 2017 2018 2017 Foreign exchange loss $ - $ - $ 20 $ -
Disclosure of finance income [text block]	Three months ended Nine months ended 2018 2017 2018 2017 Interest income $ 80 $ 21 $ 198 $ 40 Foreign exchange gain 9 48 - 102 $ 89 $ 69 $ 198 $ 142

Note 10 - Commitments, Contin_2

Note 10 - Commitments, Contingencies and Guarantees (Tables)	9 Months Ended
	Sep. 30, 2018
Statement Line Items [Line Items]
Disclosure of finance lease and operating lease by lessee [text block]	Less than 1 year 1 – 3 years 3 – 5 years Greater than 5 years Total Operating leases $ 440 $ 915 $ 706 $ - $ 2,061

Note 4 - Capital Disclosures (D

Note 4 - Capital Disclosures (Details Textual) - USD ($)	Sep. 30, 2018	May 30, 2018	Mar. 31, 2018	Mar. 28, 2018	Dec. 31, 2017
Statement Line Items [Line Items]
Maximum equity authorised			$ 100,000,000
Total cash	$ 832,000				$ 3,225,000
Total cash equivalents	$ 14,224,000				$ 7,406,000
Investments, Interest Rate	1.45%				1.45%
Aspire purchase agreement 2018 [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value		$ 20,000,000
Cantor Fitzgerald [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value				$ 30,000,000

Note 5 - Financial Instrument_2

Note 5 - Financial Instruments (Details Textual) $ in Thousands	Sep. 30, 2018USD ($)
Statement Line Items [Line Items]
Value at risk	$ 0
Floating interest rate [member]
Statement Line Items [Line Items]
Total financial liabilities	0
Forward contract [member]
Statement Line Items [Line Items]
Financial instruments designated as hedging instruments, at fair value	0
Currency risk [member]
Statement Line Items [Line Items]
Sensitivity analysis for types of market risk, reasonably possible change in risk variable, impact on pre-tax earnings	$ 78

Note 5 - Financial Instrument_3

Note 5 - Financial Instruments - Classes of Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Cash and cash equivalents, consisting of high interest savings accounts, treasury bill and short term bankers’ acceptance, classified as loans and receivables and measured at amortized cost [member]
Statement Line Items [Line Items]
Financial assets	$ 15,056	$ 10,631
Investments, consisting of fixed income securities, classified as loans and receivables and measured at amortized cost [member]
Statement Line Items [Line Items]
Financial assets	550	798
Accounts payable and accrued liabilities, measured at amortized cost [Member]
Statement Line Items [Line Items]
Financial liabilities	$ 2,370	$ 1,765

Note 5 - Financial Instrument_4

Note 5 - Financial Instruments - Currency Risk (Details) - Currency risk [member] - CAD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement Line Items [Line Items]
Balance, end of period	$ 617	$ 699
Cash and cash equivalents [member]
Statement Line Items [Line Items]
Financial assets	154	83
Invesmtents [member]
Statement Line Items [Line Items]
Financial assets	710	1,000
Accounts payable and accrued liabilities [member]
Statement Line Items [Line Items]
Accounts payable and accrued liabilities	$ (247)	$ (384)

Note 6 - Share Capital (Details

Note 6 - Share Capital (Details Textual) - USD ($)	Jun. 08, 2018	Oct. 31, 2017	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Dec. 29, 2017	May 30, 2018	Mar. 28, 2018	Oct. 27, 2017	Apr. 02, 2015
Statement Line Items [Line Items]
Issue of equity				$ 6,818,000	$ 10,203,000
Aspire purchase agreement [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value										$ 15,500,000
Total number of shares issued		357,143
Weighted average share price				2.87
Proceeds from Issuing Shares, Gross		$ 500,000		$ 15,000,000		$ 15,500,000
Proceeds from issuing shares		$ 324,000
Number of Shares Issued During the Period				5,231,953
Aspire purchase agreement [member] | Common shares to Aspire Capital in consideration for entering into the Aspire Purchase Agreement [member]
Statement Line Items [Line Items]
Total number of shares issued										321,429
Aspire purchase agreement 2018 [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value								$ 20,000,000
Total number of shares issued	170,261
Value of shares issued during the period	$ 600,000
At the market equity facility [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value											$ 20,000,000
Total number of shares issued			8,858,252		8,858,252
Weighted average share price			$ 1.20
Proceeds from Issuing Shares, Gross			10,620,000
Proceeds from issuing shares			$ 10,310,000
Equity Issuance, Commission Percentage			3.00%		3.00%
Issue of equity							$ 20,000,000
Cantor Fitzgerald [member]
Statement Line Items [Line Items]
Sale of Stock, Maximum Offering Value									$ 30,000,000
Total number of shares issued				2,017,046		2,017,046
Weighted average share price				$ 3.49
Proceeds from Issuing Shares, Gross				7,000,000
Proceeds from issuing shares				$ 6,800,000
Equity Issuance, Commission Percentage				3.00%		3.00%

Note 6 - Share Capital - Loss P

Note 6 - Share Capital - Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Issued common shares, beginning of period (in shares)	34,411	23,345	27,502	15,722
Effect of ATM issuances (in shares)	174	716	693	5,180
Effect of shares issued pursuant to share purchase agreements (in shares)			3,814
Effect of exercise of stock options (in shares)	2		30
Effect of RSUs redemptions (in shares)				52
Issued common shares, end of period (in shares)	34,587	24,061	32,039	20,954

Note 7 - Other Equity (Details

Note 7 - Other Equity (Details Textual) $ in Thousands	Jul. 13, 2018	Mar. 28, 2017	Sep. 30, 2018USD ($)shares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)shares	Sep. 30, 2017USD ($)
Statement Line Items [Line Items]
Number of share options granted in share-based payment arrangement					2,284,000	780,000
Number of shares reserved for issue under options and contracts for sale of shares | shares			6,127,965		6,127,965
First set of stock options issued in a share-based payment arrangement [member]
Statement Line Items [Line Items]
Share-based payment arrangements, option vesting percentage, year one					50.00%
Share-based payment arrangements, option vesting percentage, year two					16.67%
Share-based payment arrangements, option vesting percentage, year three					16.67%
Share-based payment arrangements, option vesting percentage, year four					16.67%
Second set of stock options issued in a share-based payment arrangement [member]
Statement Line Items [Line Items]
Share-based payment arrangements, option vesting percentage, year one					50.00%
Share-based payment arrangements, option vesting percentage, year two					25.00%
Number of share options granted in share-based payment arrangement					166,000
Share-based payment arrangements, option vesting percentage, year three					25.00%
Third set of stock options issued in a share-based payment arrangement, vesting immediately [member]
Statement Line Items [Line Items]
Number of share options granted in share-based payment arrangement					850,000
Stock options [member]
Statement Line Items [Line Items]
Expense from share-based payment transactions with employees			$ 515	$ 156	$ 3,258	$ 495
Restricted share units [member]
Statement Line Items [Line Items]
Expense from share-based payment transactions with employees			$ 437	$ 0	$ 437	$ 171
Number of other equity instruments granted in share-based payment arrangement	150,000	150,000			150,000	150,000
Share-based payment arrangements, other equity instruments, vesting period	90 days	90 days

Note 7 - Other Equity - Stock O

Note 7 - Other Equity - Stock Option Transactions (Details)	9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Statement Line Items [Line Items]
Outstanding, Beginning of period	2,344,000	2,005,000
Outstanding, Beginning of period, weighted average exercise price	$ 3.46	$ 4.31
Stock options, granted	2,284,000	780,000
Stock options, weighted average exercise price, granted	$ 2.99	$ 1.14
Stock options, exercised	(96,000)
Stock options, weighted average exercise price, exercised	$ 2.28
Stock options, forfeited	(51,000)	(165,000)
Stock options, weighted average exercise price, forfeited	$ 2.34	$ 3.34
Stock options, expired	(10,000)	(320,000)
Stock options, weighted average exercise price, expired	$ 4.97	$ 4.60
Outstanding, end of period	4,471,000	2,300,000
Outstanding, end of period, weighted average exercise price	$ 3.21	$ 3.52

Note 7 - Other Equity - Stock_2

Note 7 - Other Equity - Stock Options Outstanding (Details)	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Statement Line Items [Line Items]
Options outstanding	4,471,000	2,344,000	2,300,000	2,005,000
Options outstanding, weighted average contractual life	8.1
Options outstanding, weighted average exercise price	$ 3.21	$ 3.46	$ 3.52	$ 4.31
Options exercisable	2,559,000
Options exercisable, weighted average exercise price	$ 3.54
Range one [member]
Statement Line Items [Line Items]
Options outstanding	912,000
Options outstanding, weighted average contractual life	8.5
Options outstanding, weighted average exercise price	$ 1.45
Options exercisable	536,000
Options exercisable, weighted average exercise price	$ 1.64
Range one [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	1.03
Range one [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 2.76
Range two [member]
Statement Line Items [Line Items]
Options outstanding	687,000
Options outstanding, weighted average contractual life	9.3
Options outstanding, weighted average exercise price	$ 2.80
Options exercisable	670,000
Options exercisable, weighted average exercise price	$ 2.80
Range two [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	2.77
Range two [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 2.95
Range three [member]
Statement Line Items [Line Items]
Options outstanding	1,466,000
Options outstanding, weighted average contractual life	8.9
Options outstanding, weighted average exercise price	$ 3.06
Options exercisable	180,000
Options exercisable, weighted average exercise price	$ 2.96
Range three [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	2.96
Range three [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 3.11
Range four [member]
Statement Line Items [Line Items]
Options outstanding	704,000
Options outstanding, weighted average contractual life	6.8
Options outstanding, weighted average exercise price	$ 4.07
Options exercisable	509,000
Options exercisable, weighted average exercise price	$ 4.36
Range four [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	3.12
Range four [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 4.53
Range five [member]
Statement Line Items [Line Items]
Options outstanding	702,000
Options outstanding, weighted average contractual life	5.9
Options outstanding, weighted average exercise price	$ 5.36
Options exercisable	664,000
Options exercisable, weighted average exercise price	$ 5.36
Range five [member] | Bottom of range [member]
Statement Line Items [Line Items]
Range of exercise prices	4.54
Range five [member] | Top of range [member]
Statement Line Items [Line Items]
Range of exercise prices	$ 19.51

Note 7 - Other Equity - Stock_3

Note 7 - Other Equity - Stock Option Fair Value Assumptions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Weighted average risk-free interest rate	2.43%	1.27%
Expected dividend yield
Weighted average expected volatility	93.40%	98.40%
Weighted average expected life of options (in years)	5	5
Weighted average grant date fair value	$ 2.23	$ 0.84

Note 7 - Other Equity - Restric

Note 7 - Other Equity - Restricted Share Activity (Details) - Restricted share units [member]	Jul. 13, 2018	Mar. 28, 2017	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Statement Line Items [Line Items]
Outstanding, beginning of period
Outstanding, beginning of period, weighted average grant date fair value
Granted	150,000	150,000	150,000	150,000
Granted, weighted average grant date fair value			$ 3.35	$ 1.14
Redeemed				(150,000)
Redeemed, weighted average grant date fair value				$ 1.14
Outstanding, end of period			150,000
Outstanding, end of period, weighted average grant date fair value			$ 3.35

Note 8 - Additional Cash Flow_3

Note 8 - Additional Cash Flow Disclosures - Net Change in Non-cash Operating Working Capital (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Prepaid expenses and other assets	$ 134	$ 123	$ (63)	$ 385
Accrued payables and accrued liabilities	(33)	319	605	10
Net (used) provided	$ 101	$ 442	$ 542	$ 395

Note 9 - Other Expenses (Detail

Note 9 - Other Expenses (Details Textual) - USD ($) $ in Thousands		Jun. 13, 2018	May 07, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Research and development expense, license fee	[1],[2]					$ 5,000
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member]
Statement Line Items [Line Items]
Research and development expense, license fee			$ 2,000
CrystalGenomics [member] | Exclusive license to cg806 in China [member]
Statement Line Items [Line Items]
Research and development expense, license fee		$ 3,000
[1]	On June 13, 2018, the Company paid $3.0 million in cash to CrystalGenomics to gain an exclusive license to develop and commercialize CG-806 in China. Future milestone payments are described in note 10.
[2]	On May 7, 2018, under the license agreement with CrystalGenomics the Company, the Company paid the option fee of $2.0 million in cash to CrystalGenomics in order to exercise early the option and gain an exclusive license to develop and commercialize CG-806 in all territories outside of Korea and China. Future milestone payments are described in note 10.

Note 9 - Other Expenses - Compo

Note 9 - Other Expenses - Components of Research and Development Expenses (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Program costs, excluding salaries		$ 2,773	$ 1,017	$ 7,249	$ 2,956
Salaries		502	321	1,448	1,064
License fee, CrystalGenomics (a),(b)	[1],[2]			5,000
Stock-based compensation		307	43	826	168
Depreciation and amortization		9	9	26	25
		$ 3,591	$ 1,390	$ 14,549	$ 4,213
[1]	On June 13, 2018, the Company paid $3.0 million in cash to CrystalGenomics to gain an exclusive license to develop and commercialize CG-806 in China. Future milestone payments are described in note 10.
[2]	On May 7, 2018, under the license agreement with CrystalGenomics the Company, the Company paid the option fee of $2.0 million in cash to CrystalGenomics in order to exercise early the option and gain an exclusive license to develop and commercialize CG-806 in all territories outside of Korea and China. Future milestone payments are described in note 10.

Note 9 - Other Expenses - Com_2

Note 9 - Other Expenses - Components of General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
General and administrative excluding salaries	$ 853	$ 712	$ 3,149	$ 1,980
Salaries	503	483	1,577	1,784
Stock-based payment financing fees (note 6(a)(iii)			600
Stock-based compensation	644	112	2,869	498
Depreciation and amortization	20	12	38	40
General and administrative	$ 2,020	$ 1,319	$ 8,233	$ 4,302

Note 9 - Other Expenses - Com_3

Note 9 - Other Expenses - Components of Finance Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Foreign exchange loss			$ 20

Note 9 - Other Expenses - Com_4

Note 9 - Other Expenses - Components of Finance Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement Line Items [Line Items]
Interest income	$ 80	$ 21	$ 198	$ 40
Foreign exchange gain	9	48		102
	$ 89	$ 69	$ 198	$ 142

Note 10 - Commitments, Contin_3

Note 10 - Commitments, Contingencies and Guarantees (Details Textual) - USD ($) $ in Millions	Sep. 30, 2018	Jun. 13, 2018
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member] | Development Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment	$ 16
CrystalGenomics [member] | Exclusive license to cg806 outside of Korea and China [member] | Regulatory Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment	44
CrystalGenomics [member] | Exclusive license to cg806 in China [member] | Development Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment		$ 6
CrystalGenomics [member] | Exclusive license to cg806 in China [member] | Regulatory Milestones [Member]
Statement Line Items [Line Items]
Possible future milestone payment		$ 20
Clinical development of APTO-253 and CG'806 [member]
Statement Line Items [Line Items]
Transaction price allocated to remaining performance obligations	$ 3.5

Note 10 - Commitments, Contin_4

Note 10 - Commitments, Contingencies and Guarantees - Operating Lease Commitments (Details) $ in Thousands	Sep. 30, 2018USD ($)
Statement Line Items [Line Items]
Operating leases	$ 2,061
Not later than one year [member]
Statement Line Items [Line Items]
Operating leases	440
Later than one year and not later than three years [member]
Statement Line Items [Line Items]
Operating leases	915
Later than three years and not later than five years [member]
Statement Line Items [Line Items]
Operating leases	706
Later than five years [member]
Statement Line Items [Line Items]
Operating leases

Note 11 - Related Party Trans_2

Note 11 - Related Party Transactions (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jan. 25, 2019
Statement Line Items [Line Items]
Services to be received, related party transactions, maximum			$ 300,000
Services received, related party transactions	$ 215,000	$ 179,000

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2018	Sep. 30, 2018
Major ordinary share transactions [member] | Aspire purchase agreement 2018 [member]
Statement Line Items [Line Items]
Number of Shares Issued During the Period	707,547
Proceeds from Issuing Shares, Gross	$ 1,500,000
Cantor Fitzgerald [member]
Statement Line Items [Line Items]
Proceeds from Issuing Shares, Gross		$ 7,000,000
Cantor Fitzgerald [member] | Major ordinary share transactions [member]
Statement Line Items [Line Items]
Number of Shares Issued During the Period	1,901,279
Proceeds from Issuing Shares, Gross	$ 3,690,000